Inovio investors urged to act by April 7 deadline in securities class action over misleading statements.

The Rosen Law Firm is urging investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to secure legal counsel before the April 7, 2026 deadline to join a class action lawsuit. The lawsuit alleges that Inovio made false or misleading statements about manufacturing issues and regulatory prospects for its CELLECTRA device and INO-3107 biologics license application, which led to investor losses when the truth emerged. Investors may be entitled to compensation without upfront fees through a contingency fee arrangement. Those interested can contact the Rosen Law Firm to participate or serve as lead plaintiff in the case.